Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Regenxbio (RGNX) EBIAT (2016 - 2025)

Regenxbio has reported EBIAT over the past 12 years, most recently at -$67.1 million for Q4 2025.

  • Quarterly results put EBIAT at -$67.1 million for Q4 2025, down 31.19% from a year ago — trailing twelve months through Dec 2025 was -$193.9 million (up 14.63% YoY), and the annual figure for FY2025 was -$193.9 million, up 14.63%.
  • EBIAT for Q4 2025 was -$67.1 million at Regenxbio, down from -$61.9 million in the prior quarter.
  • Over the last five years, EBIAT for RGNX hit a ceiling of $294.0 million in Q4 2021 and a floor of -$76.7 million in Q1 2022.
  • Median EBIAT over the past 5 years was -$61.9 million (2023), compared with a mean of -$41.8 million.
  • Peak annual rise in EBIAT hit 735.85% in 2021, while the deepest fall reached 764.37% in 2021.
  • Regenxbio's EBIAT stood at $294.0 million in 2021, then plummeted by 120.38% to -$59.9 million in 2022, then dropped by 4.93% to -$62.9 million in 2023, then rose by 18.61% to -$51.2 million in 2024, then tumbled by 31.19% to -$67.1 million in 2025.
  • The last three reported values for EBIAT were -$67.1 million (Q4 2025), -$61.9 million (Q3 2025), and -$70.9 million (Q2 2025) per Business Quant data.